LLY vs VRTX · P/E 39, rev $22.97B vs P/E 30, rev $3.33B
Eli Lilly and Company (LLY) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the LLY and VRTX stock pages for the full models.
Not investment advice.